Improved survival of patients with newly diagnosed oligometastatic prostate cancer through intensified multimodal treatment

Bibliographic Details
Title: Improved survival of patients with newly diagnosed oligometastatic prostate cancer through intensified multimodal treatment
Authors: Viktoria Schütz, Christopher-Leo Nessler, Anette Duensing, Stefanie Zschäbitz, Dirk Jäger, Jürgen Debus, Markus Hohenfellner, Stefan Duensing
Source: Frontiers in Oncology, Vol 14 (2024)
Publisher Information: Frontiers Media S.A., 2024.
Publication Year: 2024
Collection: LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Subject Terms: oligometastatic prostate cancer, radical prostatectomy, multimodal treatment, intensified treatment, prostate cancer, hormone sensitive prostate cancer, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
More Details: Background and objectivesThe standard of care for patients with metastatic hormone-sensitive prostate cancer (mHSPC) includes androgen deprivation therapy (ADT), novel antihormonal therapies (NHT) and/or chemotherapy. Patients with newly diagnosed oligometastatic prostate cancer (omPCa) represent a distinct subgroup of mHSPC, for which the optimal treatment, particularly the role of radical prostatectomy (RP) and metastasis-directed therapy (MDT), is currently under debate.Materials and methodsIn this single center, retrospective analysis, 43 patients with newly diagnosed omPCa were included. All patients underwent RP as part of a multimodal, personalized treatment approach. Other treatments included ADT, NHT, MDT (surgery or radiotherapy), adjuvant radiotherapy (prostatic fossa and/or pelvic lymph nodes) or chemotherapy in various combinations. Clinical endpoints were progression free and cancer specific survival (PFS, CSS).ResultsNo patient with omPCa died from prostate cancer during an up to ten years follow-up period after intensified multimodal treatment i.e., RP, ADT, adjuvant radiation therapy and MDT (n=13). In contrast, patients requiring chemotherapy (n=10) showed a significantly worse PFS (p
Document Type: article
File Description: electronic resource
Language: English
ISSN: 2234-943X
Relation: https://www.frontiersin.org/articles/10.3389/fonc.2024.1475914/full; https://doaj.org/toc/2234-943X
DOI: 10.3389/fonc.2024.1475914
Access URL: https://doaj.org/article/55526ddb1a4544fcb376b9317bf51d81
Accession Number: edsdoj.55526ddb1a4544fcb376b9317bf51d81
Database: Directory of Open Access Journals
More Details
ISSN:2234943X
DOI:10.3389/fonc.2024.1475914
Published in:Frontiers in Oncology
Language:English